NDA 020801 · Kenvue Brands
Pepcid Ac
Famotidine · Oral
Last checked: Nov 20, 2026Latest source record: Oct 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Sep 24, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
147
23 Phase 3, 15 recruiting
FAERS reports
84,069
56,178 serious, 8,060 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2007 Supplement 12 · Efficacy ReviewLetter
- Sep 24, 1998 Original approval · Type 3 - New Dosage Form ReviewLabelLetter
2 products under this application
- PEPCID AC · FAMOTIDINE 20MG · TABLET, CHEWABLE, ORAL · Over-the-counter
- PEPCID AC · FAMOTIDINE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Famotidine" as an intervention, any sponsor and status, largest first.
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) TreatmentPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00450216 · 906 participants · Start Mar 2007 · Primary completion Aug 2008
Drug: Ibuprofen/famotidine; Ibuprofen · For: Ulcer
- Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated UlcersPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00450658 · 627 participants · Start Mar 2007 · Primary completion Sep 2008
Drug: HZT-501; Ibuprofen · For: Peptic Ulcer
- Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn EpisodesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01928888 · 559 participants · Start May 2003 · Primary completion Feb 2004
Drug: Talcid (Hydrotalcite, BAY4516H); Famotidine and 1 more · For: Heartburn
Sites: Frankfurt am Main, Germany; Dresden, Germany; Leipzig, Germany · 5 sites in all
- Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart DiseasePivotal-lookingCompleted
Ruttonjee HospitalAcademic, hospital or other
NCT00683111 · 500 participants (planned) · Start Jul 2008 · Primary completion Dec 2011
Drug: esomeprazole 20 mg daily; famotidine 40 mg daily · For: Acute Coronary Syndrome; Acute Myocardial Infarction
Sites: Hong Kong, China
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis PatientsPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT01499368 · 495 participants · Start Nov 2011 · Primary completion Nov 2012
Drug: Lafutidine; Famotidine and 1 more · For: Erosive Esophagitis
- Famotidine in Subjects With Non-erosive Gastroesophageal Reflux DiseasePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00141960 · 480 participants · Start Sep 2005
Drug: Famotidine · For: Gastroesophageal Reflux
Sites: Hokkaido Region, Japan; Kanto Region, Japan; Kinki Region, Japan · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea5,466
- fatigue5,213
- diarrhoea5,066
- chronic kidney disease4,686
- off label use4,350
- drug ineffective4,121
- dyspnoea4,001
- headache3,740
- acute kidney injury3,418
- vomiting3,314
- pain3,253
- dizziness3,130
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 743 |
| 2005 | 736 |
| 2006 | 692 |
| 2007 | 679 |
| 2008 | 850 |
| 2009 | 721 |
| 2010 | 1,023 |
| 2011 | 1,563 |
| 2012 | 1,933 |
| 2013 | 1,154 |
| 2014 | 1,431 |
| 2015 | 2,430 |
| 2016 | 2,920 |
| 2017 | 3,227 |
| 2018 | 4,565 |
| 2019 | 5,504 |
| 2020 | 6,624 |
| 2021 | 6,789 |
| 2022 | 7,276 |
| 2023 | 7,328 |
| 2024 | 8,572 |
| 2025 | 9,562 |
| 2026 | 7,743 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Histamine receptors and COVID-19.
Ennis M, Tiligada K · Inflamm Res 2021 · Systematic Review
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Agarwal SM, Stogios N, Ahsan ZA, et al. · Cochrane Database Syst Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Famotidine (Pepcid).
· Med Lett Drugs Ther 1987 · Clinical Trial
- Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.
Landry I, Aluri J, Hall N, et al. · Pharmacol Res Perspect 2020 · Clinical Trial, Phase I, Clinical Trial, Phase III
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Leary PJ, Rayner SG, Branch KRH, et al. · Chest 2025 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Cheema HA, Shafiee A, Athar MMT, et al. · J Infect 2023 · Meta-Analysis, Systematic Review
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.